GLP-1s & Weight Loss

Liraglutide

Evidence

What is liraglutide?

Liraglutide is a long-acting GLP-1 receptor agonist. It copies some of the effects of a natural hormone called GLP-1, which helps control appetite, fullness, blood sugar, insulin release, glucagon release and how quickly food leaves the stomach.

Natural GLP-1 disappears from the body within minutes. Liraglutide was designed to resist rapid breakdown and last much longer. Its half-life is about 13 hours, which makes once-daily dosing possible.

Liraglutide is the active ingredient in products used for different purposes:

• Saxenda for long-term weight management
• Victoza and other liraglutide diabetes products for type 2 diabetes

Liraglutide is peptide-based, an incretin mimetic and a GLP-1 receptor agonist. It is not insulin, a stimulant, a GIP agonist or a glucagon agonist.

Its weight-management effects mainly come from reducing appetite, increasing fullness and lowering food intake. It has not been shown to work by dramatically increasing how many calories the body burns.

How well studied is it?

Very well studied in humans. Liraglutide has large randomized human trials, FDA-approved products, established clinical dosing, long-term human follow-up, cardiovascular research, pediatric studies and well-described safety information. Major weight-management trials commonly lasted 56 weeks, and some participants were followed for up to 160 weeks.

Evidence level

Overall evidence rating: strong human evidence

• Strong evidence for: GLP-1 receptor activation, reduced appetite, weight loss, long-term weight management, type 2 diabetes treatment, once-daily SC dosing, gradual titration, cardiovascular benefit in specific diabetes populations, and major safety risks.
• Limited or unproven for: only taking it when hungry, every-other-day use, bedtime superiority, fasting superiority, split dosing, bodybuilding, athletic enhancement, spot fat loss, receptor-reset cycles, and stacking with other GLP-1 drugs.

Primary research focus

• Best established: long-term weight management, type 2 diabetes, appetite reduction, blood sugar control, cardiovascular-risk reduction in selected diabetes patients.
• Also studied: waist circumference, blood pressure, lipid markers, prediabetes, long-term obesity treatment.
• Not established: athletic performance, bodybuilding, spot fat loss, injury repair, only taking it when appetite returns.

What may it help with?

• Weight loss and long-term weight management: Saxenda is FDA approved, together with diet and physical activity, to help eligible adults and adolescents lose excess weight and maintain weight reduction. In one major 56-week obesity trial, average weight loss was about 8.4 kg with liraglutide 3 mg compared with 2.8 kg with placebo.
• Reduced appetite and increased fullness: liraglutide decreases appetite, increases fullness and makes it easier to stop eating sooner. This is one of the main reasons it helps with weight management.
• Blood sugar control: liraglutide is FDA approved to improve blood sugar control in adults and children aged 10 years and older with type 2 diabetes.
• Cardiovascular risk reduction: diabetes-dose liraglutide has an FDA indication to reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. This does not automatically apply to everyone using Saxenda only for weight management.

Additional human evidence (secondary outcomes): Saxenda trials found greater reductions in waist circumference than placebo, obesity studies found modest average improvements in blood pressure, and some other cardiometabolic measures such as lipids also improved.

What has it not been proven to help with?

Liraglutide has not been established as a treatment for:

• bodybuilding or muscle growth
• athletic performance
• injury recovery
• spot fat loss or selectively burning belly fat
• directly increasing metabolism
• guaranteed energy improvement
• occasional "as needed" appetite control
• producing the same weight-loss result at every dose
• permanently preventing weight regain after stopping

Dosing evidence

Clinical / FDA-approved dosing

There are two major liraglutide dosing systems, and they are separate: Saxenda for weight management and Victoza (or other diabetes liraglutide) for type 2 diabetes.

Saxenda (weight management): adult label titration

The label maintenance dose for adults is 3 mg SC once daily. The lower doses are used to work up to 3 mg gradually, mainly to reduce stomach-related side effects. If a dose increase is not tolerated, the next increase can be delayed by about one extra week. If an adult cannot tolerate 3 mg daily, the current Saxenda label says treatment should be discontinued.

For adult Saxenda, 1.8 mg and 2.4 mg are titration doses. 1.8 mg is not the standard adult Saxenda maintenance dose, and 2.4 mg is the week-4 titration dose, not a "fat-loss threshold".

Victoza / diabetes liraglutide: adult label dosing

• Start: 0.6 mg SC once daily for one week
• Then: 1.2 mg once daily
• If more blood sugar control is needed: 1.8 mg once daily, after at least one week at 1.2 mg

The 0.6 mg dose is mainly a starting dose to reduce stomach-related side effects. In adults it is not considered an effective dose for blood sugar control. Saxenda's 3 mg maintenance dose is not part of the diabetes protocol.

Product details (Saxenda)

Timing and injection sites

The label allows liraglutide once daily at any time of day, with or without food. It is injected under the skin of the abdomen, thigh or upper arm, and injection sites should be rotated.

Missed dose (Saxenda label)

If one dose is missed, the label says to take the next dose at the normal scheduled time, without an extra dose. If more than 3 days have passed since the last Saxenda dose, the label says to restart at 0.6 mg daily and repeat the dose-escalation schedule to reduce GI side effects.

Frequency

Once daily, for both Saxenda and diabetes liraglutide products. Twice-daily split dosing, every-other-day dosing, 5 days on / 2 days off, and taking it only when hungry are not established.

Duration and cycling

Liraglutide is designed for ongoing treatment, not short peptide-style cycles. Major weight-management studies lasted about 56 weeks, with some longer research extending to 160 weeks. No receptor-reset cycle has been established, and there is no proven need for 8 weeks on / 4 weeks off, 12-week cycles, 5 days on / 2 days off, or 2–4 week receptor resets.

Research-community dosing

Because liraglutide already has a detailed approved protocol, community use usually changes how quickly the dose is increased rather than creating a different dosing system. Community practices include staying at one dose longer if nausea is strong, increasing more slowly, and not increasing while appetite suppression remains strong, sometimes staying below 3 mg. These practices have not been validated in clinical trials.

Protocol comparison

The strongest agreement across sources is once-daily SC use with gradual titration. The main source of confusion is mixing Saxenda doses, Victoza doses, titration doses and maintenance doses; they are separate.

Does the route match the research?

Yes. Saxenda, diabetes liraglutide and the major human trials all use subcutaneous injection.

Expected results timeline

Clinical research

• First few weeks: liraglutide starts working right away, and appetite and fullness may change while the dose is being increased. The first four weeks are also the titration period, so early weight-loss results vary.
• Week 16: the current Saxenda label uses an adult response checkpoint 16 weeks after starting treatment. If an adult has not lost at least 4% of starting body weight by then, the label recommends stopping treatment because meaningful long-term weight loss is unlikely.
• Week 56: major weight-management studies commonly measured their main results at 56 weeks. In the SCALE obesity trial, average weight loss was about 8.4 kg with liraglutide and about 2.8 kg with placebo.
• Up to week 160: some participants with abnormal blood sugar measurements were followed for up to 160 weeks.

For weight management, results are measured in months, not days.

Commonly reported community timeline

• Days to a few weeks: less hunger or feeling full sooner.
• Several weeks: gradual changes on the scale.
• Several months: more noticeable changes in body weight and waist size.

These are community descriptions, not controlled averages from clinical trials. Because liraglutide has strong human outcome data, the clinical timeline is the primary reference.

Protocol logic check

Does once-daily dosing make sense?

Yes. Both major liraglutide uses are built around once-daily SC dosing, and daily use creates the steady repeated exposure the tested schedule relies on. This is strongly evidence-supported.

Twice-daily or every-other-day dosing

There is no established benefit to splitting liraglutide into a morning and an evening dose. Every-other-day dosing is not a validated protocol: skipping a full day creates larger swings in drug exposure than the tested daily schedule.

Bedtime, fasted and workout timing

The label allows any time of day, and there is no evidence that bedtime dosing produces better weight loss, appetite reduction or blood sugar control. Liraglutide does not need to be taken fasted, and there is no demonstrated reason to time it before or after exercise.

Dose escalation / titration

For liraglutide, titration is supported by clinical evidence and labeling. Saxenda starts at 0.6 mg and increases weekly to 3 mg, mainly to reduce stomach-related side effects. This differs from compounds where titration is only a community habit.

Is 1.8 mg the standard maintenance dose?

It depends on the use. For type 2 diabetes, it can be: diabetes liraglutide uses 1.2 mg or 1.8 mg depending on blood sugar control. For adult Saxenda weight management, no: the label maintenance dose is 3 mg daily, and 1.8 mg is part of the titration schedule.

Cycles, receptor resets and washouts

Clinical studies lasted much longer than 8–12 weeks, including 56 weeks and up to 160 weeks in some participants. Some effects of GLP-1 drugs can change with long-term treatment; for example, the effect on stomach emptying may become less pronounced over time. That does not mean the GLP-1 receptor needs a scheduled break, and long-term weight-management benefit has been shown with continued treatment. There is no validated 2-week washout, 4-week break or receptor recovery period for ongoing treatment.

Can it be taken only when hunger returns?

That does not match the tested clinical protocol, which is consistent once-daily use rather than large doses separated by long gaps, irregular dosing or dosing only when hunger returns.

Mechanism and pharmacokinetics

What does liraglutide target?

Liraglutide activates the GLP-1 receptor. After food enters the body, natural GLP-1 helps signal that food has arrived, so the body controls blood sugar and reduces the drive to keep eating. Liraglutide creates a much longer-lasting version of that signal. This mechanism is well established.

How long does it stay in the body?

Liraglutide has a half-life of about 13 hours. After a Saxenda injection, the drug reaches its highest blood level at about 11 hours. This long exposure is why liraglutide is designed for one injection every day, rather than several injections per day, every-other-day use or once-weekly use. One daily injection provides clinically useful GLP-1 signaling across the day.

What studies have found

SCALE Obesity and Prediabetes

A large randomized trial compared liraglutide 3 mg once daily with placebo, alongside lifestyle changes. At 56 weeks, average weight loss was about 8.4 kg with liraglutide and about 2.8 kg with placebo. This supports 3 mg adult weight-management dosing, once-daily use, long-term treatment and meaningful average weight loss. It does not support taking it only when hungry, random microdosing, every-other-day dosing, or assuming 0.6 mg gives the same long-term effect.

SCALE Diabetes

Adults with type 2 diabetes were assigned to liraglutide 3 mg, liraglutide 1.8 mg or placebo. Average weight loss was about 6.4 kg with 3 mg, 5.0 kg with 1.8 mg and 2.2 kg with placebo. Dose can affect weight-loss results, so 1.8 mg and 3 mg are not interchangeable protocols.

Long-term weight management

Saxenda trials commonly lasted 56 weeks, with some participants followed for 160 weeks. The SCALE Maintenance trial studied continued liraglutide treatment after initial diet-induced weight loss. Liraglutide is designed as a long-term treatment rather than a short peptide cycle.

Cardiovascular research

Liraglutide has been studied in adults with type 2 diabetes and established cardiovascular disease, and the diabetes indication includes reducing major cardiovascular events in this specific population. This does not give Saxenda a general cardiovascular indication for everyone using it for weight management.

Three liraglutide situations that are often mixed together

• Saxenda: long-term weight management; adult maintenance 3 mg once daily after titration.
• Victoza / diabetes liraglutide: type 2 diabetes; typical adult treatment doses are 1.2 mg or 1.8 mg once daily.
• Research / compounded liraglutide: a research vial or compounded product does not automatically share Saxenda's storage, concentration, sterility, pen dosing accuracy or 30-day in-use stability.

Storage

Saxenda pen

Approved liraglutide comes as a ready-to-use liquid (Saxenda: 18 mg in 3 mL, 6 mg/mL, clear and colorless, in a single-patient-use prefilled pen for subcutaneous use only). It does not need to be mixed with bacteriostatic water, and research-vial mixing instructions do not apply to approved pens.

• Before first use: store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze.
• After first use: the pen can be stored for 30 days at 15°C to 30°C (59°F to 86°F) or refrigerated at 2°C to 8°C (36°F to 46°F).
• Keep the cap on and protect the pen from excessive heat and sunlight.
• Remove the needle after every injection.
• Discard the pen after 30 days, even if medication remains.

Research or compounded liraglutide

Saxenda's 6 mg/mL concentration, 30-day storage rule, sterility and pen accuracy do not automatically apply to research vials, compounded multidose vials, lyophilized liraglutide or products mixed with bacteriostatic water. Storage and handling instructions for the exact product apply.

Contraindications

Formal FDA contraindications

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Serious hypersensitivity to liraglutide or product ingredients

Important cautions

• Pancreatitis: an important warning, but a history of pancreatitis is not listed as a formal current Saxenda contraindication.
• Severe gastroparesis: Saxenda is not recommended, rather than formally contraindicated.
• Kidney disease / dehydration: kidney impairment itself is not a blanket contraindication. The main concern is kidney injury caused or worsened by dehydration from severe GI side effects.
• Diabetes medications: insulin and sulfonylureas can increase the risk of low blood sugar.
• Pregnancy: not listed as a formal Saxenda contraindication, but weight loss provides no benefit during pregnancy, the label warns of possible fetal harm, and Saxenda should be stopped when pregnancy is recognized.
• Planned surgery or deep sedation: the procedural team needs to know about liraglutide because it can slow stomach emptying.

Suicidal ideation: 2026 label change

Older Saxenda information may still list suicidal behavior or suicidal thoughts as a warning. That information is outdated. In February 2026, the FDA approved removal of this warning from Saxenda's prescribing information, after a broader FDA review found that the available evidence did not support a causal link between GLP-1 receptor agonists and suicidal thoughts or behavior. A history of suicidal ideation or prior suicide attempts is not a current Saxenda contraindication or risk flag.

Side effects

Common effects

Common Saxenda effects include nausea, diarrhea, constipation, vomiting, injection-site reactions, headache, indigestion, fatigue, dizziness, abdominal pain and increased lipase. Stomach-related side effects are especially common while the dose is being increased.

Important safety concerns

• Thyroid C-cell tumors: liraglutide caused thyroid C-cell tumors in animal studies. It is not known whether it causes these tumors in humans, which is why it is contraindicated with a personal or family history of MTC or MEN 2.
• Pancreatitis: acute pancreatitis has been reported with GLP-1 receptor agonists including liraglutide. Severe or persistent abdominal pain needs medical assessment.
• Gallbladder disease: increased risk of gallstones and gallbladder inflammation.
• Hypoglycemia: most relevant when liraglutide is combined with insulin, sulfonylureas or other medicines that increase insulin release, rather than liraglutide alone.
• Increased heart rate: Saxenda can increase resting heart rate.
• Kidney injury from dehydration: severe or ongoing nausea, vomiting or diarrhea can cause dehydration, which can contribute to acute kidney injury.
• Severe GI effects: Saxenda can cause severe gastrointestinal side effects and is not recommended in severe gastroparesis.
• Serious allergic reactions: anaphylaxis and angioedema have been reported.
• Aspiration during anesthesia or deep sedation: because liraglutide slows stomach emptying, food may remain in the stomach longer than expected. Rare aspiration events have been reported during general anesthesia or deep sedation.

Regulatory status

Compatibility

Stack / pairing logic

Sources

1. DailyMed. Saxenda (liraglutide) injection, current FDA-approved labeling. Weight-management indication, 0.6 to 3 mg escalation, adult 3 mg maintenance, once-daily SC route, meal-independent timing, contraindications, current warnings, 16-week adult response check, formulation, storage and 30-day in-use period. dailymed.nlm.nih.gov
2. DailyMed. Victoza (liraglutide) injection, FDA-approved diabetes labeling. 0.6 mg starting dose, 1.2 mg treatment dose, optional increase to 1.8 mg, once-daily SC use at any time of day independent of meals, type 2 diabetes indication, cardiovascular-risk reduction in adults with type 2 diabetes and established cardiovascular disease, approximately 13-hour half-life. dailymed.nlm.nih.gov
3. Pi-Sunyer et al. SCALE Obesity and Prediabetes. Randomized human clinical trial: liraglutide 3 mg, 56-week weight-loss outcomes. pubmed.ncbi.nlm.nih.gov/26132939
4. Davies et al. SCALE Diabetes. Randomized human clinical trial: comparison of 3 mg and 1.8 mg, dose-related weight-loss differences in people with type 2 diabetes. pubmed.ncbi.nlm.nih.gov/26284720
5. Wadden et al. SCALE Maintenance. Randomized human clinical research: longer-term weight maintenance with continued liraglutide after initial diet-induced weight loss. pubmed.ncbi.nlm.nih.gov/23812094
6. U.S. FDA. Saxenda supplement approval letter, 2026. Regulatory action removing the suicidal-behavior and ideation warning from Saxenda labeling. accessdata.fda.gov